| Title |
Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
|
|---|---|
| Published in |
Discover Nano, January 2018
|
| DOI | 10.1186/s11671-017-2420-2 |
| Pubmed ID | |
| Authors |
Sebastien Benizri, Ludivine Ferey, Bruno Alies, Naila Mebarek, Gaelle Vacher, Ananda Appavoo, Cathy Staedel, Karen Gaudin, Philippe Barthélémy |
| Abstract |
Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility (< 5 μM), toxicity, and side effects issues of this drug. In this context, the use of nanocarriers is currently investigated in order to overcome these drawbacks. In this contribution, we report a new type of sorafenib-based nanoparticles stabilized by hybrid nucleoside-lipids. The solid lipid nanoparticles (SLNs) showed negative or positive zeta potential values depending on the nucleoside-lipid charge. Transmission electron microscopy of sorafenib-loaded SLNs revealed parallelepiped nanoparticles of about 200 nm. Biological studies achieved on four different cell lines, including liver and breast cancers, revealed enhanced anticancer activities of Sorafenib-based SLNs compared to the free drug. Importantly, contrast phase microscopy images recorded after incubation of cancer cells in the presence of SLNs at high concentration in sorafenib (> 80 μM) revealed a total cancer cell death in all cases. These results highlight the potential of nucleoside-lipid-based SLNs as drug delivery systems. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 17% |
| Student > Master | 5 | 14% |
| Researcher | 3 | 9% |
| Professor | 3 | 9% |
| Professor > Associate Professor | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 13 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 23% |
| Chemistry | 5 | 14% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Environmental Science | 2 | 6% |
| Earth and Planetary Sciences | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 13 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2023.
All research outputs
#8,538,940
of 25,382,440 outputs
Outputs from Discover Nano
#228
of 1,149 outputs
Outputs of similar age
#161,198
of 450,898 outputs
Outputs of similar age from Discover Nano
#4
of 18 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,149 research outputs from this source. They receive a mean Attention Score of 3.5. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,898 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.